RENOWN NEWSROOM

Clinical researchers with the Healthy Nevada Project co-author research paper with findings that emphasize the need for a comprehensive approach to breast cancer risk assessment – including a focus on genetic medicine – to help ensure that individuals at high risk are identified and supported proactively rather than reactively.  Breast cancer is a leading cause of cancer death among women in the United States. According to the American Cancer Society, about 1 in 8 women will develop breast cancer and about 1 in 39 women will die from breast cancer. Breast cancer is associated with increased age, hereditary factors, obesity, and alcohol use. Since 1990, breast cancer death rates have declined progressively due to advancements in treatment and detection. In Nevada there are an estimated 2,310 new breast cancer cases a year, and genetic mutations such as in the genes BRCA1 or BRCA2 remain a top risk factor for this prevalent disease. Recognizing the urgency for progress in breast cancer research, a collaborative effort between physicians, advanced practice providers and scientists from the Healthy Nevada Project® (HNP) and Helix have unveiled groundbreaking research. This study explores how genetic screenings are a necessary supplement to traditional testing methods, together offering more accurate insights into a patient's likelihood of developing breast cancer in the future. HNP is operated by Renown Genomic Medicine and the Institute for Health Innovation and is one of the largest community-based population health studies in the country. Their team works in collaboration with Helix, a leader in precision health that delivers comprehensive genomic solutions. Together, this dynamic partnership aims to understand breast cancer risk factors and pave the way for more effective preventative measures. The combined research team studied 25,591 female HNP participants to evaluate the performance of different genetic screening approaches to identify women at high risk of breast cancer. The results of this research suggest that a combined monogenic, or single-gene, and polygenic, or multi-gene, approach to breast cancer screenings helped produce more accurate results and more closely identify study participants who have a high genetic risk of developing the disease. "Based on this research, we are advocating a shift in approach which would improve breast cancer risk assessment through a combination of effective family history ascertainment and genetic screening,” said Joseph Grzymski, PhD, principal investigator of the Healthy Nevada Project, research professor at the University of Nevada, Reno School of Medicine and co-author of the breast cancer research paper. “This tailored approach, founded on the assessment of individual genetic risk, not only intends to elevate patient well-being but also will improve efficiency and equity in healthcare." Complementing the team’s research on leveraging genetics to identify women at low genetic risk of breast cancer that could safely defer mammogram screenings by five to 10 years that was released in late 2023 in JAMA Oncology, the study suggests that incorporating genetic information can assist in personalizing breast cancer screenings and optimizing the use of screening resources. "Existing disparities persist across various facets of breast cancer screening and treatment; however, genetic screening is clearly a powerful tool to help facilitate early intervention for those at higher risk,” said Jamie Schnell Blitstein, APRN, a primary care nurse practitioner at Renown Health and co-author of the breast cancer research paper. “By placing a heightened focus on risk, we underscore the pivotal role of preventative breast cancer screening.” Despite the availability of effective methods for early screening, co-authors of this research found that 78 percent of women with a family history of breast cancer had their risk ascertained only after a breast cancer diagnosis. The findings emphasize the need for a comprehensive approach to breast cancer risk assessment – including a focus on genetic medicine – to help ensure that individuals at high risk are identified and supported proactively rather than reactively.  “These findings that can profoundly impact how healthcare is delivered were only made possible by all the participants who were willing to consent to research,” said Alex Bolze, PhD from Helix and co-author of the publication. “Broad-scale collaboration projects like these between Renown Health and UNR that engage large populations where participants share both their genetic information as well as electronic health records drive advancements in preventative medicine, as well as fundamental biological research.”   The research paper was officially accepted on Jan. 29, 2024, and will be published by Elsevier, Inc. on behalf of the American College of Medical Genetics and Genomics. The contents of the paper will appear in the international journal Genetics in Medicine Open. Read the full article by visiting sciencedirect.com. The Healthy Nevada Project is currently recruiting new study participants. Free to all Nevadans with a saliva sample or blood draw, participants and their referring providers receive access to whole-exome sequencing and clinical grade results that help provide insight into their unique genetic risks tied to heart disease and certain cancers. If you are interested in enrolling in the study, schedule a Virtual Consent Appointment through MyChart or contact the Renown Institute for Health Innovation at RenownIHI@renown.org or (775) 982-6914 to be connected to a Genomic Representative. About Renown Health Renown Health is the region’s largest, not-for-profit integrated healthcare network serving Nevada, Lake Tahoe and northeast California. With a diverse workforce of more than 7,000 employees, Renown has fostered a longstanding culture of excellence, determination and innovation. The organization comprises a trauma center, two acute care hospitals, a children’s hospital, a rehabilitation hospital, a medical group and urgent care network, and the region’s largest, locally owned not-for-profit insurance company, Hometown Health. Renown is currently enrolling participants in the largest community-based genetic population health study, the Healthy Nevada Project®. To join the Renown Health team, visit renown.org/careers. About Helix Helix is the leading population genomics and viral surveillance company operating at the intersection of clinical care, research, and data analytics. Helix enables health systems, life sciences companies, payers, and government partners to accelerate the integration of genomic data into patient care and public health decision-making. Learn more at helix.com.

Read More About Research Shows Genetic Approaches to Breast Cancer Screenings Yield More Accurate Results

Renown Health is pleased to announce that Kate A. Ward, Pharm.D., BCPS, has been promoted to serve as Vice President, Oncology for Renown Regional Medical Center.    Dr. Ward has over fourteen years of service to the organization, most recently as Director of Clinical Pharmacy responsible for the oversight of all clinical pharmacy activities at Renown Regional Medical Center, Renown South Meadows Medical Center, and Renown Rehabilitation Hospital. Additionally, Dr. Ward is the Residency Director of the Post-Graduate Year 1 (PGY1) Pharmacy Practice Residency at Renown. Over the last decade at Renown, Dr. Ward has served as Pharmacy Clinical Manager, Pharmacy Clinical Coordinator and Clinical Pharmacist.   Dr. Ward will bring her pharmacy clinical service experience (including ICU, Outpatient Infusion, Pediatrics, Oncology and Emergency Services), Inpatient Care, Clinical Research, and Hospital Formulary Management, Electronic Medical Record Integration and Optimization to this important new role.   As a dyad partner with Max J. Coppes, MD, PhD, MBA, Director of the William N. Pennington Cancer Institute at Renown, she will bring her clinical, operational, regulatory, and administrative experience to lead the oncology division. Dr. Ward, Dr. Coppes and the dedicated team will advance Renown’s mission to expand care, prevention, screening, research, and education with the goal of establishing the first National Institutes of Health, NCI designated Cancer Center for our State.   “We are thrilled to welcome Dr. Ward as our new Vice President of Oncology. She brings a wealth of experience and a passion for advancing patient care. Dr. Ward will play a pivotal role in sharing the future our oncology division and furthering our commitment to providing exceptional care,” said Chris Nicholas, CEO of Renown Regional Medical Center.    As a licensed pharmacist, Dr. Ward holds a Doctor of Pharmacy degree from the University of Colorado, Health Sciences Center. The Pharm.D. is a professional degree like a Doctor of Medicine (MD) or Doctor of Dental Surgery (DDS). As a doctorate, it represents the increasing responsibility pharmacists have in healthcare systems and the high trust Americans have in pharmacists.    Dr. Ward completed her residency at Stanford Hospital and Clinics. She graduated from the University of Nevada, Reno with her bachelor’s degree in Nutritional Sciences. Dr. Ward is active in several professional associations and currently serves as a Pharmacy Board member for HealthTrust; Vice Chair of the American Society of Health System Pharmacists® Council on Therapeutics; and Vice Chair for the Silver State Scripts Board for the State of Nevada. Dr. Ward was the 2022 recipient of the Nevada Society of Health System Pharmacists (NVSHP) President’s Award. About Renown Health Renown Health is the region’s largest, locally governed, not-for-profit integrated healthcare network serving Nevada, Lake Tahoe and northeast California. With a diverse workforce of more than 7,000 employees, Renown has fostered a longstanding culture of excellence, determination and innovation. The organization comprises a trauma center, two acute care hospitals, a children’s hospital, a rehabilitation hospital, a medical group and urgent care network, and the locally owned not-for-profit insurance company, Hometown Health. To join the Renown Health team, visit renown.org/careers.

Read More About Exceptional Talent Joins William N. Pennington Cancer Institute at Renown; Dr. Kate Ward Brings Expertise and Vision as Vice President of Oncology Division

Renown Medical Group is thrilled to welcome two distinguished breast surgical oncologists, Colleen O'Kelly-Priddy, MD and Michelle K. Chu, MD to the team. These highly skilled breast surgeons will solely focus on providing breast care and therefore play a pivotal role in Renown Health’s William N. Pennington Cancer Institute’s commitment to provide subspecialized care to the people living in our community and beyond. Dr. Colleen O'Kelly-Priddy is a fellowship-trained, board-certified breast surgical oncologist with an impressive background in breast cancer surgery. Dr. Priddy was born at Washoe Medical Center (which later became Renown Regional Medical Center) and grew up in Susanville, CA before attending Stanford University for her undergraduate studies. She is a graduate of the University of Nevada, Reno School of Medicine. "I am thrilled to return to Reno to help increase access to world-class surgical breast cancer care,” said Dr. Priddy. “My focus is to provide exceptional care, particularly for young people with breast cancer. I am excited to continue my mission here in northern Nevada." Dr. Michelle K. Chu, a board-certified general surgeon, brings her extensive experience in advanced breast cancer treatment to the Renown team. Dr. Chu received her undergraduate degree from the University of Pennsylvania and her medical degree from Western Reserve School of Medicine in Cleveland, OH. Dr. Chu specializes in oncoplastic breast conserving surgery and nipple sparing mastectomies. "I believe in tailoring treatment options to each patient's unique needs,” Dr. Chu said. “Whether it's preserving the natural shape of the breast or supporting the 'Going Flat' movement, our team strives to provide the best possible outcome for every patient." The newest addition to the William N. Pennington Cancer Institute, Renown Breast Surgery Care provides comprehensive breast surgery care at 1500 E. 2nd Street in Reno, adjacent to the Renown Regional Medical Center campus. "Breast cancer accounts for approximately 20% of newly diagnosed cancer cases in Washoe County, with roughly 520 new cases annually, establishing it as the most prevalent cancer type within our community,” says Brian Erling, MD, MBA, President & CEO, Renown Health. “We are proud, as the community’s largest not-for-profit healthcare system, to invest in cancer prevention and early diagnoses, including mammography screening and genetic research. For those diagnosed with breast cancer, Renown now offers two superb breast surgeons specializing in breast preservation surgery, and a breast surgery center providing comprehensive, compassionate care. Our goal is to save women’s lives, save families and ensure better care and better outcomes. This is a major step forward for women’s healthcare and our community.” As part of this expansion, Renown is assuming operations of Reno Surgical Advocates, a respected private practice in Reno. "Access to expert breast cancer care close to home is crucial, and our dedicated team at Renown Breast Surgery Care will work tirelessly to provide the highest level of care to patients while working closely with our other cancer specialists," said Max Coppes, MD, PhD, MBA, Director, William N. Pennington Institute for Cancer. “With the exceptional expertise of Dr. Colleen O'Kelly-Priddy and Dr. Michelle K. Chu, coupled with our state-of-the-art facility; Renown Health is a true partner in the fight against breast cancer in northern Nevada.” "People are increasingly relocating to northern Nevada, and in fact, Washoe County experienced a 2.1% population growth from April 2020 to July 2022. Consequently, although northern Nevada does not exhibit an above-average cancer rate, we are observing a rise in cases at our facilities," said Dr. Lee Schwartzberg, MD, FACP, Section Chief of Medical Oncology at the William N. Pennington Cancer Institute. "Renown Health is positioned to meet this growing demand, and we take pride in consistently adding nationally renowned healthcare providers to our team to save the lives of women in northern Nevada.     About Renown Health Renown Health is the region’s largest, locally governed, not-for-profit integrated healthcare network serving Nevada, Lake Tahoe, and northeast California. With a diverse workforce of more than 7,000 employees, Renown has fostered a longstanding culture of excellence, determination, and innovation. The organization comprises a trauma center, two acute care hospitals, a children’s hospital, a rehabilitation hospital, a medical group and urgent care network, and the region’s largest, locally owned not-for-profit insurance company, Hometown Health.

Read More About Saving More Lives; Renown Expands Breast Cancer Care, Adding Two Best-In-Class Breast Surgeons

Recognized as one of the world’s leading breast cancer experts as a 2023 Legends in Cancer Honoree Dr. Lee Schwartzberg, FACP, Section Chief of Medical Oncology at the William N. Pennington Cancer Institute at Renown, was honored as the 2023 Legends in Cancer honoree at this year's Best of Breast conference for his contributions to the field of breast cancer. The conference took place on Jan. 21 and 22. Breast cancer is a leading cause of cancer death among women in the United States. According to the American Cancer Society, about 1 in 8 women will develop breast cancer and about 1 in 36 women will die from breast cancer. Breast cancer is associated with increased age, hereditary factors, obesity, and alcohol use. Since 1990, breast cancer death rates across the country, and here in Washoe County have declined progressively due to advancements in treatment, detection, and care. Each year in the United States, about 264,000 cases of breast cancer are diagnosed in women and about 2,400 in men. Here in Washoe County, more than 21 deaths per 100,000 females are due to breast cancer, a significant decrease since 2012 when 24 deaths per 100,000 females were reported. Dr. Schwartzberg was selected for this award based on his unique and vast contributions to advancing science and patient care, including his major research interests such as therapeutic approaches to breast cancer, targeted therapies, and supportive care. The selection committee evaluates each candidates’ body of work — including contributions to the field of breast cancer in clinical research, patient care, mentoring and community service — before deciding on an honoree. “Dr. Schwartzberg is deserving of this honor. As a national expert in the study and treatment of breast cancer, precision medicine and supportive care, Dr. Schwartzberg is transforming cancer care and improving the lives of all of us in northern Nevada. As the most preferred cancer program in the region, we are working with the support of donors like The William N. Pennington Foundation to recruit additional oncology specialists and cancer science researchers to become the first National Cancer Institute-designated comprehensive cancer care center in Nevada," said Dr. Brian Erling, MBA, CEO of Renown Health. “The incredible care that comes from the William N. Pennington Cancer Institute is possible because of nationally recognized oncologists like Dr. Schwartzberg.” “Dr. Schwartzberg completed fellowship training in medical oncology and hematology at Memorial Sloan Kettering Cancer Center in New York, where he also served as Chief Medical Resident and was a founding member of the institutional ethics committee,” add Paul J. Hauptman, MD, dean of the University of Nevada, Reno School of Medicine and chief academic officer for Renown Health. “We are proud that he serves as a professor of clinical medicine at the University of Nevada, Reno School of Medicine. His research interests include supportive care, precision medicine and patient-reported outcomes in breast cancer and he has published over 300 peer-reviewed manuscripts, book chapters and monographs.” “It is an honor to work with Dr. Schwartzberg and his patients have the most incredible things to say about the care he provides.” said Dr. Max J Coppes, PhD, MBA, Director, William N. Pennington Cancer Institute, Renown Health. “He understands that his patients are going through one of the most challenging times in their lives. Dr. Schwartzberg brings decades of experience to our community, is a great listener, and treats everyone with compassion and dignity. We are so proud to have him at Renown.” The Best of Breast Conference is an innovative medical education program that gathers the world's leading breast cancer experts to discuss cases with high-risk characteristics, adjuvant and metastatic treatment advances, interdisciplinary care and survivorship and recurrence — all while incorporating data from the major oncologic annual meetings. Dr. Schwartzberg has been selected to chair Total Health’s spring oncology education retreat in Lake Tahoe on April 15 and 16. The event’s comprehensive agenda will allow attendees to engage with the latest research and strategies in cancer care while networking with colleagues from across the country in a peaceful setting. Additional conference information is available here. For women, breast exams using mammography after 40 years old is recommended. For those age 75 and older, a mammogram is recommended every year. Having regular mammograms can lower the risk of dying from breast cancer. Both 3-D digital mammography and whole breast ultrasounds are available at the Greenberg Breast Health Center at Renown and other locations across northern Nevada. The Affordable Care Act makes breast cancer screening and counseling free. All health plans must cover these benefits at no cost to you. Renown MyChart app users can self-schedule a mammogram appointment. To call to schedule, dial 775-982-8100. At the William N. Pennington Cancer Institute at Renown Health, patients receive innovative, personalized treatment to fight cancer while an experienced team provides the support and technology to maintain the highest quality of life. The Renown team’s clinical expertise and advanced treatment options blend evidence-based care with leading-edge research to improve cancer outcomes for every patient and family. For more information or a referral, visit renown.org/cancer. About Renown Health Renown Health is Nevada’s largest, not-for-profit integrated healthcare network serving Nevada, Lake Tahoe, and northeast California. With a diverse workforce of more than 7,000 employees, Renown has fostered a longstanding culture of excellence, determination, and innovation. The organization comprises a trauma center, two acute care hospitals, a children’s hospital, a rehabilitation hospital, a medical group and urgent care network, and the locally owned not-for-profit insurance company, Hometown Health. Renown is currently enrolling participants in a community-based genetic population health study, the Healthy Nevada Project®. About Total Health Total Health is a medical information company of planning experts who produce tailored content, courses, and conferences for oncology healthcare providers, virtual and in-person. Total Health believes knowledge is power. Its mission is to give oncology healthcare providers an educational experience that equips them with the latest strategies to improve clinical practice and treatment outcomes.

Read More About Dr. Lee Schwartzberg Honored With 2023 Legends in Cancer Award